Great Promise of Tissue-Resident Adult Stem/Progenitor Cells in Transplantation and Cancer Therapies

  • Murielle MimeaultEmail author
  • Surinder K. Batra
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 741)


Recent progress in tissue-resident adult stem/progenitor cell research has inspired great interest because these immature cells from your own body can act as potential, easily accessible cell sources for cell transplantation in regenerative medicine and cancer therapies. The use of adult stem/progenitor cells endowed with a high self-renewal ability and multilineage differentiation potential, which are able to regenerate all the mature cells in the tissues from their origin, offers great promise in replacing non-functioning or lost cells and regenerating diseased and damaged tissues. The presence of a small subpopulation of adult stem/progenitor cells in most tissues and organs provides the possibility of stimulating their in vivo differentiation, or of using their ex vivo expanded progenies for cell-replacement and gene therapies with multiple applications in humans without a high-risk of graft rejection and major side effects. Among the diseases that could be treated by adult stem cell-based therapies are hematopoietic and immune disorders, multiple degenerative disorders such as Parkinson’s and Alzheimer’s diseases, Types 1 and 2 diabetes mellitus as well as skin, eye, liver, lung, tooth and cardiovascular disorders. In addition, a combination of the current cancer treatments with an adjuvant treatment consisting of an autologous or allogeneic adult stem/progenitor cell transplantation also represents a promising strategy for treating and even curing diverse aggressive, metastatic, recurrent and lethal cancers. In this chapter, we reviewed the most recent advancements on the characterization of phenotypic and functional properties of adult stem/progenitor cell types found in bone marrow, heart, brain and other tissues and discussed their therapeutic implications in the stem cell-based transplantation therapy.


Stem Cell Mesenchymal Stem Cell Neural Stem Cell Endothelial Progenitor Cell Injured Spinal Cord 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6:93–106.PubMedCrossRefGoogle Scholar
  2. 2.
    Moore KA, Lemischka IR. Stem cells and their niches. Science 2006; 311:1880–1885.PubMedCrossRefGoogle Scholar
  3. 3.
    Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005; 85:1373–1416.PubMedCrossRefGoogle Scholar
  4. 4.
    Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Cardiol 2010; 50:296–303.PubMedCrossRefGoogle Scholar
  5. 5.
    Bernardo ME, Emons JA, Karperien M et al. Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res 2007; 48:132–140.PubMedCrossRefGoogle Scholar
  6. 6.
    Watts C, McConkey H, Anderson L, Caldwell M. Anatomical perspectives on adult neural stem cells. J Anat 2005; 207:197–208.PubMedCrossRefGoogle Scholar
  7. 7.
    Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004; 10:S42–S50.PubMedCrossRefGoogle Scholar
  8. 8.
    Lim DA, Huang YC, Alvarez-Buylla A. The adult neural stem cell niche: lessons for future neural cell replacement strategies. Neurosurg Clin N Am 2007; 18:81–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Mimeault M, Batra SK. Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 2006; 24:2319–2345.PubMedCrossRefGoogle Scholar
  10. 10.
    Mimeault M, Batra SK. Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev 2008; 4:27–49.PubMedCrossRefGoogle Scholar
  11. 11.
    Mimeault M, Hauke R, Batra SK. Stem cells—A revolution in therapeutics—Recent advances on the stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther 2007; 82:252–264.PubMedCrossRefGoogle Scholar
  12. 12.
    Ahmed F, Arseni N, Glimm H et al. Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells 2008; 26:810–818.PubMedCrossRefGoogle Scholar
  13. 13.
    Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotechnol 2005; 23:857–861.PubMedCrossRefGoogle Scholar
  14. 14.
    Mimeault M, Batra SK. Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer. Gut 2008; 57:1456–1468.PubMedCrossRefGoogle Scholar
  15. 15.
    Kaltz N, Ringe J, Holzwarth C et al. Novel markers of mesenchymal stem cells defined by genome-wide gene expression analysis of stromal cells from different sources. Exp Cell Res 2010; 316:2609–2617.PubMedCrossRefGoogle Scholar
  16. 16.
    Castellani C, Padalino M, China P et al. Bone-marrow-derived CXCR4-positive tissue-committed stem cell recruitment in human right ventricular remodeling. Hum Pathol 2010; 41:1566–1576.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen L, Wu F, Xia WH et al. CXCR4 gene transfer contributes to in vivo reendothelialization capacity of endothelial progenitor cells. Cardiovasc Res 2010; 88:462–470.PubMedCrossRefGoogle Scholar
  18. 18.
    Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol 2006; 169:338–346.PubMedCrossRefGoogle Scholar
  19. 19.
    Ringden O. Immunotherapy by allogeneic stem cell transplantation. Adv Cancer Res 2007; 97C:25–60.CrossRefGoogle Scholar
  20. 20.
    Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood 2008; 111:4446–4455.PubMedCrossRefGoogle Scholar
  21. 21.
    Yoon J, Choi SC, Park CY et al. Bone marrow-derived side population cells are capable of functional cardiomyogenic differentiation. Mol Cells 2008; 25:216–223.PubMedGoogle Scholar
  22. 22.
    Pu DR, Liu L. HDL slowing down endothelial progenitor cells senescence: a novel anti-atherogenic property of HDL. Med Hypotheses 2008; 70:338–342.PubMedCrossRefGoogle Scholar
  23. 23.
    Fan Y, Shen F, Frenzel T et al. Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol 2010; 67:488–497.PubMedCrossRefGoogle Scholar
  24. 24.
    Hou HY, Liang HL, Wang YS et al. A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions. Mol Ther 2010; 45:1–]LiteraturGoogle Scholar
  25. 25.
    Wakitani S, Okabe T, Horibe S et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011; 5:146–150.PubMedCrossRefGoogle Scholar
  26. 26.
    Povsic TJ, O’Connor CM. Cell therapy for heart failure: the need for a new therapeutic strategy. Expert Rev Cardiovasc Ther 2010; 8:1107–1126.PubMedCrossRefGoogle Scholar
  27. 27.
    Hatzistergos KE, Quevedo H, Oskouei BN et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010; 107:913–922.PubMedCrossRefGoogle Scholar
  28. 28.
    Martinez-Cerdeno V, Noctor SC, Espinosa A et al. Embryonic MGE precursor cells grafted into adult rat striatum integrate and ameliorate motor symptoms in 6-OH DA-lesioned rats. Cell Stem Cell 2010; 6:238–250.PubMedCrossRefGoogle Scholar
  29. 29.
    Venkataramana NK, Kumar SK, Balaraju S et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. Transl Res 2010; 155: 62–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Blurton-Jones M, Kitazawa M, Martinez-Coria H et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 2009; 106:13594–13599.PubMedCrossRefGoogle Scholar
  31. 31.
    Yamane J, Nakamura M, Iwanami A et al. Transplantation of galectin-1-expressing human neural stem cells into the injured spinal cord of adult common marmosets. J Neurosci Res 2010; 88:1394–1405.PubMedGoogle Scholar
  32. 32.
    Massouh M, Saghatelyan A. De-routing neuronal precursors in the adult brain to sites of injury: role of the vasculature. Neuropharmacology 2010; 58:877–883.PubMedCrossRefGoogle Scholar
  33. 33.
    Sugaya K, Kwak YD, Ohmitsu O et al. Practical issues in stem cell therapy for Alzheimer’s disease. Curr Alzheimer Res 2007; 4:370–377.PubMedCrossRefGoogle Scholar
  34. 34.
    Bragina O, Sergejeva S, Serg M et al. Smoothened agonist augments proliferation and survival of neural cells. Neurosci Lett 2010; 482:81–85.PubMedCrossRefGoogle Scholar
  35. 35.
    Karimi-Abdolrezaee S, Eftekharpour E, Wang J et al. Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. J Neurosci 2010; 30:1657–1676.PubMedCrossRefGoogle Scholar
  36. 36.
    Lepski G, Jannes CE, Strauss B et al. Survival and neuronal differentiation of mesenchymal stem cells transplanted into the rodent brain are dependent upon microenvironment. Tissue Eng Part A 2010.Google Scholar
  37. 37.
    Six EM, Bonhomme D, Monteiro M et al. A human postnatal lymphoid progenitor capable of circulating and seeding the thymus. J Exp Med 2007; 204:3085–3093.PubMedCrossRefGoogle Scholar
  38. 38.
    Dor FJ, Ramirez ML, Parmar K et al. Primitive hematopoietic cell populations reside in the spleen: studies in the pig, baboon, and human. Exp Hematol 2006; 34:1573–1582.PubMedCrossRefGoogle Scholar
  39. 39.
    Konuma T, Oguro H, Iwama A. Role of the polycomb group proteins in hematopoietic stem cells. Dev Growth Differ 2010; 52:505–516.PubMedCrossRefGoogle Scholar
  40. 40.
    Brave M, Farrell A, Ching LS et al. FDA review summary: mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 2010; 78:282–288.PubMedCrossRefGoogle Scholar
  41. 41.
    Rossi DJ, Bryder D, Weissman IL. Hematopoietic stem cell aging: mechanism and consequence. Exp Gerontol 2007; 42:385–390.PubMedCrossRefGoogle Scholar
  42. 42.
    Barfield RC, Hale GA, Burnette K et al. Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48:349–353.PubMedCrossRefGoogle Scholar
  43. 43.
    Vogel W, Kopp HG, Kanz L et al. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 2005; 131:214–218.PubMedCrossRefGoogle Scholar
  44. 44.
    Petersen SL. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Dan Med Bull 2007; 54:112–139.PubMedGoogle Scholar
  45. 45.
    Hausermann P, Walter RB, Halter J et al. Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology 2008; 216:287–304.PubMedCrossRefGoogle Scholar
  46. 46.
    Krause DS, Lazarides K, von Andrian UH et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006; 12:1175–1180.PubMedCrossRefGoogle Scholar
  47. 47.
    Sellheyer K, Krahl D. Skin mesenchymal stem cells: Prospects for clinical dermatology. J Am Acad Dermatol 2010; 63:859–865.PubMedCrossRefGoogle Scholar
  48. 48.
    Tu TC, Kimura K, Nagano M et al. Identification of human placenta-derived mesenchymal stem cells involved in re-endothelialization. J Cell Physiol 2010; 226:224–235.Google Scholar
  49. 49.
    Gindraux F, Selmani Z, Obert L et al. Human and rodent bone marrow mesenchymal stem cells that express primitive stem cell markers can be directly enriched by using the CD49a molecule. Cell Tissue Res 2007; 327:471–483.PubMedCrossRefGoogle Scholar
  50. 50.
    Martin J, Helm K, Ruegg P et al. Adult lung side population cells have mesenchymal stem cell potential. Cytotherapy 2008; 10:140–151.PubMedCrossRefGoogle Scholar
  51. 51.
    Shanti RM, Li WJ, Nesti LJ et al. Adult mesenchymal stem cells: biological properties, characteristics, and applications in maxillofacial surgery. J Oral Maxillofac Surg 2007; 65:1640–1647.PubMedCrossRefGoogle Scholar
  52. 52.
    Yoshikawa T, Mitsuno H, Nonaka I et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg 2008; 121:860–877.PubMedCrossRefGoogle Scholar
  53. 53.
    Wang CH, Cherng WJ, Yang NI et al. Late-outgrowth endothelial cells attenuate ntimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 2007; 28:54–60.PubMedCrossRefGoogle Scholar
  54. 54.
    Haider HK, Elmadbouh I, Jean-Baptiste M et al. Non-viral vector gene modification of stem cells for myocardial repair. Mol Med 2008; 14:79–86.PubMedCrossRefGoogle Scholar
  55. 55.
    Tang J, Wang J, Zheng F et al. Combination of chemokine and angiogenic factor genes and mesenchymal stem cells could enhance angiogenesis and improve cardiac function after acute myocardial infarction in rats. Mol Cell Biochem 2010; 339:107–118.PubMedCrossRefGoogle Scholar
  56. 56.
    McMullen NM, Pasumarthi KB. Donor cell transplantation for myocardial disease: does it complement current pharmacological therapies-Can J Physiol Pharmacol 2007; 85:1–15.PubMedCrossRefGoogle Scholar
  57. 57.
    Sohn RL, Jain M, Liao R. Adult stem cells and heart regeneration. Expert Rev Cardiovasc Ther 2007; 5:507–517.PubMedCrossRefGoogle Scholar
  58. 58.
    Ahmadi H, Baharvand H, Ashtiani SK et al. Safety analysis and improved cardiac function following local autologous transplantation of CD133(-) enriched bone marrow cells after myocardial infarction. Curr Neurovasc Res 2007; 4:153–160.PubMedCrossRefGoogle Scholar
  59. 59.
    Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132:645–660.PubMedCrossRefGoogle Scholar
  60. 60.
    Kandasamy M, Couillard-Despres S, Raber KA et al. Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-beta signaling in an animal model of Huntington disease. J Neuropathol Exp Neurol 2010; 69:717–728.PubMedCrossRefGoogle Scholar
  61. 61.
    Pardal R, Ortega-Saenz P, Duran R et al. Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. Cell 2007; 131:364–377.PubMedCrossRefGoogle Scholar
  62. 62.
    Delcroix GJ, Schiller PC, Benoit JP et al. Adult cell therapy for brain neuronal damages and the role of tissue engineering. Biomaterials 2010; 31:2105–2120.PubMedCrossRefGoogle Scholar
  63. 63.
    Lee ST, Chu K, Park JE et al. Intravenous administration of human neural stem cells induces functional recovery in Huntington’s disease rat model. Neurosci Res 2005; 52:243–249.PubMedCrossRefGoogle Scholar
  64. 64.
    Keene CD, Chang RC, Lopez-Yglesias AH et al. Suppressed accumulation of cerebral amyloid ta peptides in aged transgenic Alzheimer’s disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol 2010; 177:346–354.Google Scholar
  65. 65.
    Lee HJ, Lee JK, Lee H et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol Aging 2010:in press.Google Scholar
  66. 66.
    Freedman MS, Bar-Or A, Atkins HL et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010; 16:503–510.PubMedCrossRefGoogle Scholar
  67. 67.
    Murrell W, Wetzig A, Donnellan M et al. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson’s disease. Stem Cells 2008; 26:2183–2192.PubMedCrossRefGoogle Scholar
  68. 68.
    Jones J, Jaramillo-Merchan J, Bueno C et al. Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. Neurobiol Dis 2010; 40:415–423.PubMedCrossRefGoogle Scholar
  69. 69.
    Harms KM, Li L, Cunningham LA. Murine neural stem/progenitor cells protect neurons against ischemia by HIF-1alpha-regulated VEGF signaling. PLoS ONE 2010; 5:e9767.PubMedCrossRefGoogle Scholar
  70. 70.
    Zou Z, Jiang X, Zhang W et al. Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson’s disease—a rat model study. Brain Res 2010; 1346:279–286.PubMedCrossRefGoogle Scholar
  71. 71.
    Oh JS, Ha Y, An SS et al. Hypoxia-preconditioned adipose tissue-derived mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model. Neurosci Lett 2010; 472:215–219.PubMedCrossRefGoogle Scholar
  72. 72.
    Somoza R, Juri C, Baes M et al. Intranigral transplantation of epigenetically-induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson s disease. Biol Blood Marrow Transplant 2010; 16:1530–1540.PubMedCrossRefGoogle Scholar
  73. 73.
    Chang DY, Yoo SW, Hong Y et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010; 127:1975–1983.PubMedCrossRefGoogle Scholar
  74. 74.
    Kim SU. Neural Stem Cell-based Gene Therapy for Brain Tumors. Stem Cell Rev 2011; 7:130–140.PubMedCrossRefGoogle Scholar
  75. 75.
    Wu W, Chen X, Hu C et al. Transplantation of neural stem cells expressing hypoxia-inducible factor-1alpha (HIF-1alpha) improves behavioral recovery in a rat stroke model. J Clin Neurosci 2010; 17:92–95.PubMedCrossRefGoogle Scholar
  76. 76.
    Mercapide J, Rappa G, Anzanello F et al. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. Int J Cancer 2010; 126:1206–1215.PubMedGoogle Scholar
  77. 77.
    Rattigan Y, Hsu JM, Mishra PJ et al. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp Cell Res 2010; 316:3417–3424.PubMedCrossRefGoogle Scholar
  78. 78.
    Ehtesham M, Kabos P, Kabosova A et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002; 62:5657–5663.PubMedGoogle Scholar
  79. 79.
    Ehtesham M, Kabos P, Gutierrez MA et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002; 62: 7170–7174.PubMedGoogle Scholar
  80. 80.
    Mercapide J, Rappa G, Anzanello F et al. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. Int J Cancer 2010; 126:1206–1215.PubMedGoogle Scholar
  81. 81.
    Wu DC, Byod AS, Wood KJ. Embryonic stem cell transplantation: potential applicability in cell replacement therapy and regenerative medicine. Front Biosci 2007; 12:4525–4535.PubMedCrossRefGoogle Scholar
  82. 82.
    Trivedi HL, Vanikar AV, Thakker U et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc 2008; 40:1135–1139.PubMedCrossRefGoogle Scholar
  83. 83.
    Hida N, Nishiyama N, Miyoshi S et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells 2008; 26:1695–1704.PubMedCrossRefGoogle Scholar
  84. 84.
    Meng X, Ichim TE, Zhong J et al. Endometrial regenerative cells: a novel stem cell population. J Transl Med 2007; 5:57.PubMedCrossRefGoogle Scholar
  85. 85.
    Loebinger MR, Eddaoudi A, Davies D et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69:4134–4142.PubMedCrossRefGoogle Scholar
  86. 86.
    Zischek C, Niess H, Ischenko I et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009; 250:747–753.PubMedCrossRefGoogle Scholar
  87. 87.
    Davidoff AM, Ng CY, Brown P et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001; 7:2870–2879.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  1. 1.Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied DiseasesUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations